Is pandrug-resistance in A. baumannii a transient phenotype? Epidemiological clues from a 4-year cohort study at a tertiary referral hospital in Greece
- PMID: 33124498
- DOI: 10.1080/1120009X.2020.1839689
Is pandrug-resistance in A. baumannii a transient phenotype? Epidemiological clues from a 4-year cohort study at a tertiary referral hospital in Greece
Abstract
Pandrug-resistant A. baumannii (PDRAB) is increasingly being reported but remains rare. Several case studies show that A. baumannii can acquire resistance to last resort antibiotics during treatment by single-step chromosomal mutations. However, re-emergence of the ancestral susceptible strain after withdrawal of antibiotics has been described, possibly due to fitness cost associated with acquired resistance. Therefore, PDRAB may be a transient phenotype. Epidemiological data to show this process in larger cohorts are currently lacking. In this study of 91 hospitalized patients with PDRAB we showed the frequent (60%) isolation of non-PDRAB, often susceptible only to colistin, aminoglycosides and/or tigecycline, preceding and/or following PDRAB isolation. However, the isolation of PDRAB in two outpatients, 25 and 36 days after their discharge from the hospital, suggests the potential of some PDRAB strains to persist even in the absence of antimicrobial pressure.
Keywords: Acinetobacter baumannii; PDR; epidemiology; pandrug-resistant; resistance.
Similar articles
-
Excess mortality due to pandrug-resistant Acinetobacter baumannii infections in hospitalized patients.J Hosp Infect. 2020 Nov;106(3):447-453. doi: 10.1016/j.jhin.2020.09.009. Epub 2020 Sep 11. J Hosp Infect. 2020. PMID: 32927013
-
Epidemiological investigation after hospitalising a case with pandrug-resistant Acinetobacter baumannii infection.J Hosp Infect. 2009 May;72(1):30-5. doi: 10.1016/j.jhin.2009.02.003. Epub 2009 Mar 12. J Hosp Infect. 2009. PMID: 19282051
-
Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan.J Formos Med Assoc. 2003 Sep;102(9):601-6. J Formos Med Assoc. 2003. PMID: 14625603
-
Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology.Int J Antimicrob Agents. 2015 Jun;45(6):568-85. doi: 10.1016/j.ijantimicag.2015.03.001. Epub 2015 Mar 24. Int J Antimicrob Agents. 2015. PMID: 25857949 Review.
-
Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.Int J Antimicrob Agents. 2012 Feb;39(2):105-14. doi: 10.1016/j.ijantimicag.2011.10.004. Epub 2011 Nov 22. Int J Antimicrob Agents. 2012. PMID: 22113193 Review.
Cited by
-
Genomic and Phenotypic Evolution of Tigecycline-Resistant Acinetobacter baumannii in Critically Ill Patients.Microbiol Spectr. 2022 Feb 23;10(1):e0159321. doi: 10.1128/spectrum.01593-21. Epub 2022 Jan 19. Microbiol Spectr. 2022. PMID: 35044218 Free PMC article.
-
Systematic review and meta-analysis of the proportion and associated mortality of polymicrobial (vs monomicrobial) pulmonary and bloodstream infections by Acinetobacter baumannii complex.Infection. 2021 Dec;49(6):1149-1161. doi: 10.1007/s15010-021-01663-0. Epub 2021 Jul 14. Infection. 2021. PMID: 34260054
-
In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.Infection. 2022 Jun;50(3):569-581. doi: 10.1007/s15010-021-01748-w. Epub 2022 Jan 4. Infection. 2022. PMID: 34982411
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources